Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
5.26
+0.26 (5.20%)
Nov 20, 2024, 4:00 PM EST - Market closed
Company Description
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain.
Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy.
In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases.
Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
Serina Therapeutics, Inc.
| Country | United States |
| Founded | 2017 |
| IPO Date | Nov 29, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Steven Ledger |
Contact Details
Address: 601 Genome Way, Suite 2001 Huntsville, Alabama 35806 United States | |
| Phone | 256 327 9630 |
| Website | serinatherapeutics.com |
Stock Details
| Ticker Symbol | SER |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001708599 |
| ISIN Number | US81751A1088 |
| Employer ID | 82-1436829 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Steven A. Ledger | Chief Executive Officer and Director |
| Dr. Randall W. Moreadith M.D., Ph.D. | Chief Development Officer |
| Dr. Balkrishan Gill Ph.D. | Executive Chairman |
| Dr. Srini Tenjarla | Senior Vice President of Chemistry, Manufacturing and Controls and Formulation |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Nov 6, 2024 | ARS | Filing |
| Nov 6, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 6, 2024 | DEF 14A | Other definitive proxy statements |
| Oct 31, 2024 | DEFC14A | Filing |
| Oct 2, 2024 | 8-K | Current Report |
| Sep 12, 2024 | 8-K | Current Report |
| Sep 5, 2024 | 8-K | Current Report |